Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9694 USD | +1.77% | +11.27% | -9.40% |
Mar. 21 | Transcript : MiNK Therapeutics, Inc., Q4 2023 Earnings Call, Mar 21, 2024 | |
Mar. 21 | MiNK Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 33.06M |
---|---|---|---|---|---|
Net income 2024 * | -19M | Net income 2025 * | -36M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.85
x | P/E ratio 2025 * |
-1.44
x | Employees | 31 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 28.66% |
Latest transcript on MiNK Therapeutics, Inc.
1 day | +1.77% | ||
1 week | +11.27% | ||
Current month | -2.08% | ||
1 month | +3.13% | ||
3 months | +7.83% | ||
6 months | -5.88% | ||
Current year | -9.40% |
Managers | Title | Age | Since |
---|---|---|---|
Jennifer Buell
CEO | Chief Executive Officer | 50 | 21-01-31 |
Heather Boussios
CMP | Compliance Officer | - | - |
Marc van Dijk
CTO | Chief Tech/Sci/R&D Officer | 61 | 20-02-29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Garo Armen
CHM | Chairman | 71 | 17-06-30 |
Director/Board Member | 66 | 17-06-30 | |
Barbara Ryan
BRD | Director/Board Member | 64 | 21-08-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-02 | 0.9694 | +1.77% | 37 865 |
24-05-01 | 0.9525 | -3.79% | 80,462 |
24-04-30 | 0.99 | +4.20% | 34,268 |
24-04-29 | 0.9501 | +2.44% | 58,345 |
24-04-26 | 0.9275 | +6.46% | 32,366 |
Delayed Quote Nasdaq, May 02, 2024 at 03:51 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.40% | 33.06M | |
+25.77% | 42.68B | |
-3.86% | 42.4B | |
+45.32% | 40.04B | |
-6.20% | 28.31B | |
+6.81% | 24.94B | |
-21.68% | 18.96B | |
+27.90% | 12.3B | |
-2.85% | 11.95B | |
-1.86% | 11.55B |
- Stock Market
- Equities
- INKT Stock